Medicines Source unknown
Dealstreet

Rajani, Vertices act on La Renon Healthcare investment in Enaltec Labs

The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Bar & Bench

La Renon Healthcare, a pharmaceutical company has acquired 51% stake in Enaltec Labs. The deal values Enaltec at a post-money valuation of ₹180-200 crore.

Rajani Associates advised La Renon Healthcare and the team included:

  • Transation Team - Poorvi Sanjanwala (Partner), Nishtha Mehta (Senior Associate), Kashmira Bakliwal (Senior Associate) and Rutvik Rajagopal (Associate)

  • Diligence Team - Ankur Singhania (Partner), Kashmira Bakliwal, Rohan Gajaria and Rutvik Rajagopal.

Vertices Partners advised Enaltec Labs with a team led by Partners Amit Manubarwala and Vishal Mehta.

Managing Partner, Vinayak Burman provided strategic inputs.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Husband forcing wife to quit job is cruelty: Madhya Pradesh High Court

Supreme Court refuses to entertain PIL for probe into death of Subhas Chandra Bose

BJP leader seeks time to correct another defective affidavit in defamation suit against Dhruv Rathee

Luthra advises First Coffee on $1.2 million fundraise

Khaitan Legal Associates advises Synergy Capital on equity acquisition in Afcons Infrastructure

SCROLL FOR NEXT